Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: Results of the nationwide HEPNET. Greece cohort study

Gut

Volumn 60, Issue 8, 2011, Pages 1109-1116

  Papatheodoridis, George V ^a   Manolakopoulos, Spilios ^a   Touloumi, Giota ^a   Vourli, Georgia ^a   Raptopoulou Gigi, Maria ^b   Vafiadis Zoumbouli, Irini ^a   Vasiliadis, Themistoklis ^b   Mimidis, Kostas ^c   Gogos, Charalambos ^d   Ketikoglou, Ioannis ^e   Manesis, Emanuel K ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^d UNIVERSITY OF PATRAS   (Greece)

^e KAT HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ANTIVIRUS AGENT; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; PEGINTERFERON ALPHA;

ADULT; AGE; ARTICLE; CANCER CENTER; CANCER INCIDENCE; CANCER REGRESSION; CANCER RISK; COHORT ANALYSIS; DISEASE SEVERITY; FEMALE; FOLLOW UP; GENDER; GREECE; HEPATITIS B; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; VIRUS INHIBITION;

ADMINISTRATION, ORAL; ADULT; AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; GREECE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INCIDENCE; LAMIVUDINE; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS;

EID: 79960302035     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2010.221846     Document Type: Article

References (30)

1. Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-39. (Pubitemid 46374607)
2. Papatheodoridis GV, Manolakopoulos S, Dusheiko G, et al. Therapeutic strategies in the management of patients with chronic hepatitis B. Lancet Infect Dis 2008;8:167-78. (Pubitemid 351249242)
3. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-42.
4. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-76. (Pubitemid 46890874)
5. Schafer DF, Sorrell MF. Hepatocellular carcinoma. Lancet 1999;353:1253-7. (Pubitemid 29168472)
6. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73. (Pubitemid 43042691)
7. Dienstag JL, Goldin RD, Heathcote EJ, et al. Histologic outcome during long-term lamivudine therapy. Gastroenterology 2003;124:105-17. (Pubitemid 36055344)
8. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006;131:1743-51. (Pubitemid 44958517)
9. Yokosuka O, Takaguchi K, Fujioka S, et al. Long-term use of entecavir in nucleosidenaive Japanese patients with chronic hepatitis B infection. J Hepatol 2010;52:791-9.
10. Liaw Y-F, Chang T-T, Wu S-S, et al. Long-term entecavir therapy results in reversal of fibrosis/cirrhosis and continued histologic improvement in patients with HBeAg(+) and (-) chronic hepatitis B: Results from studies ETV-022, -027 and -901. Hepatology 2008;48(Suppl):706A.
11. Craxi A, Di Bona D, Camma C. Interferon-a for HBeAg-positive chronic hepatitis B. J Hepatol 2003;39(Suppl 1):S99-105.
12. Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-a treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 2001;34:306-13. (Pubitemid 32176454)
13. Lampertico P, Del Ninno E, Vigano M, et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology 2003;37:756-63. (Pubitemid 36397385)
14. Lin SM, Yu ML, Lee CM, et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 2007;46:45-52.
15. Yuen MF, Hui CK, Cheng CC, et al. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology 2001;34:139-45.
16. Sung JJ, Tsoi KK, Wong VW, et al. Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2008;28:1067-77.
17. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-31.
18. Raptopoulou M, Papatheodoridis G, Antoniou A, et al. Epidemiology, course and disease burden of chronic hepatitis B virus infection. HEPNET study for chronic hepatitis B: a multicentre Greek study. J Viral Hepat 2009;16:195-202.
19. Manesis EK, Papatheodoridis GV, Touloumi G, et al. Natural course of treated and untreated chronic HCV infection: results of the nationwide Hepnet. Greece cohort study. Aliment Pharmacol Ther 2009;29:1121-30.
20. Papatheodoridis GV, Dimou E, Dimakopoulos K, et al. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 2005;42:121-9. (Pubitemid 40911319)
21. Saldanha J, Gerlich W, Lelie N, et al. An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques. Vox Sanguinis 2001;80:63-71.
22. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-36. (Pubitemid 43112690)
23. Okuda K. Hepatocellular carcinoma. J Hepatol 2000;32(Suppl 1):225-37. (Pubitemid 30123637)
24. Di Marco V, Marzano A, Lampertico P, et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 2004;40:883-91. (Pubitemid 39288121)
25. Papatheodoridis GV, Lampertico P, Manolakopoulos S, et al. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 2010;53:348-56.
26. Yang HI, Sherman M, Su J, et al. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Clin Oncol 2010;28:2437-44.
27. Shafritz DA, Shouval D, Sherman HI, et al. Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem tissue specimens. N Engl J Med 1981;305:1067-73. (Pubitemid 12234831)
28. Laurent-Puig P, Legoix P, Bluteau O, et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 2001;120:1763-73. (Pubitemid 32523494)
29. Andreone P, Gramenzi A, Cursaro C, et al. High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing lamivudine resistance. J Viral Hepat 2004;11:439-42. (Pubitemid 39336225)
30. Di Marco V, Di Stefano R, Ferraro D, et al. HBV-DNA suppression and disease course in HBV cirrhosis patients on long-term lamivudine therapy. Antivir Ther 2005;10:431-9. (Pubitemid 41151021)